| 94282-1 |
Cat recombinant (rFel d) 7 Ab.IgE.RAST class |
PrThr |
Ser |
Pt |
Ord |
|
|
DEPRECATED |
Deprecated Cat recombinant (rFel d) 7 IgE Ab RAST class [Presence] in Serum |
|
DEL |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ALLERGY |
|
94282-1 |
|
|
|
|
Both |
|
|
|
0 |
Deprecated Cat (rFel d) 7 IgE RAST Ql |
|
|
|
|
|
ABS; Aby; Allergen; Allergens; ALLERGY TESTING; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Cat (rFel d) 7; Dextro; e231; Feline; Felis domesticus; IgE RAST; Immune globulin E; Immunoglobulin E; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Serum; SR |
2.75 |
2.68 |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
| 94283-9 |
Dipeptidyl aminopeptidase-like protein 6 Ab.IgG |
PrThr |
CSF |
Pt |
Ord |
CBA IFA |
|
ACTIVE |
Dipeptidyl aminopeptidase-like protein 6 IgG Ab [Presence] in Cerebral spinal fluid by Cell binding immunofluorescent assay |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SERO |
|
94283-9 |
|
CBA IFA |
|
|
Both |
|
|
|
0 |
DPPX IgG CSF Ql CBA IFA |
|
|
|
|
|
ABS; Aby; Amiopep; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Cerebral spinal fluid; Cerebrospinal Fl; Dipeptidyl peptidase-like protein 6; Dipeptidyl peptidase-like protein 6 Ab; Dipeptidyl peptidase-like protein 6 IgG; DPPX; DPPX Ab; Immune globulin G; Immunoglobulin G; Indirect Fluorescence Antibody; Neuro; Neurology; Ordinal; Point in time; PR; Prot; QL; Qual; Qualitative; Random; Screen; Serology; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid |
2.69 |
2.68 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 94284-7 |
Dipeptidyl aminopeptidase-like protein 6 Ab.IgG |
Titr |
CSF |
Pt |
SemiQn |
IF |
|
ACTIVE |
Dipeptidyl aminopeptidase-like protein 6 IgG Ab [Titer] in Cerebral spinal fluid by Immunofluorescence |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
SERO |
|
94284-7 |
|
IF |
|
|
Both |
|
|
|
0 |
DPPX IgG Titr CSF IF |
|
|
|
|
|
ABS; Aby; ACIF; Amiopep; Antby; Anti; Antibodies; Antibody; Anticomplement Immunofluorescence; Autoantibodies; Autoantibody; Cerebral spinal fluid; Cerebrospinal Fl; Dilution factor; Dilution Factor (Titer); Dipeptidyl peptidase-like protein 6; Dipeptidyl peptidase-like protein 6 Ab; Dipeptidyl peptidase-like protein 6 IgG; DPPX; DPPX Ab; FA; Fluorescent antibody; Fluoresent; IFA; Immune fluorescence; Immune globulin G; Immunoflour; Immunofluor; Immunofluorescence; Immunoglobulin G; Neuro; Neurology; Point in time; PR; Prot; Random; Serology; SmQn; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid; Time Resolved Fluorescence; Titer; Titered; Titre; TRF; Ttr |
2.75 |
2.68 |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
| 94285-4 |
Contactin-associated protein 2 Ab.IgG |
PrThr |
Ser |
Pt |
Ord |
CBA IFA |
|
ACTIVE |
Contactin-associated protein 2 IgG Ab [Presence] in Serum by Cell binding immunofluorescent assay |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SERO |
|
94285-4 |
|
CBA IFA |
|
|
Both |
|
|
|
0 |
CASPR2 IgG Ser Ql CBA IFA |
|
|
|
|
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Assoc; Autoantibodies; Autoantibody; CASPR2; CASPR2 Ab; II; Immune globulin G; Immunoglobulin G; Indirect Fluorescence Antibody; Neuro; Neurology; Ordinal; Point in time; PR; Prot; QL; Qual; Qualitative; Random; Screen; Serology; Serum; SR |
2.69 |
2.68 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 94286-2 |
Contactin-associated protein 2 Ab.IgG |
PrThr |
CSF |
Pt |
Ord |
CBA IFA |
|
ACTIVE |
Contactin-associated protein 2 IgG Ab [Presence] in Cerebral spinal fluid by Cell binding immunofluorescent assay |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SERO |
|
94286-2 |
|
CBA IFA |
|
|
Both |
|
|
|
0 |
CASPR2 IgG CSF Ql CBA IFA |
|
|
|
|
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Assoc; Autoantibodies; Autoantibody; CASPR2; CASPR2 Ab; Cerebral spinal fluid; Cerebrospinal Fl; II; Immune globulin G; Immunoglobulin G; Indirect Fluorescence Antibody; Neuro; Neurology; Ordinal; Point in time; PR; Prot; QL; Qual; Qualitative; Random; Screen; Serology; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid |
2.69 |
2.68 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 94287-0 |
Leucine-rich glioma-inactivated protein 1 Ab.IgG |
PrThr |
Ser |
Pt |
Ord |
CBA IFA |
|
ACTIVE |
Leucine-rich glioma-inactivated protein 1 IgG Ab [Presence] in Serum by Cell binding immunofluorescent assay |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SERO |
|
94287-0 |
|
CBA IFA |
|
|
Both |
|
|
|
0 |
LGI1 IgG Ser Ql CBA IFA |
|
|
|
|
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; i; Immune globulin G; Immunoglobulin G; Indirect Fluorescence Antibody; Leu; LGI1; LGI1 Ab; Neuro; Neurology; Ordinal; Point in time; PR; Prot; QL; Qual; Qualitative; Random; Screen; Serology; Serum; SR |
2.69 |
2.68 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 94288-8 |
Leucine-rich glioma-inactivated protein 1 Ab.IgG |
PrThr |
CSF |
Pt |
Ord |
CBA IFA |
|
ACTIVE |
Leucine-rich glioma-inactivated protein 1 IgG Ab [Presence] in Cerebral spinal fluid by Cell binding immunofluorescent assay |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SERO |
|
94288-8 |
|
CBA IFA |
|
|
Both |
|
|
|
0 |
LGI1 IgG CSF Ql CBA IFA |
|
|
|
|
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Cerebral spinal fluid; Cerebrospinal Fl; i; Immune globulin G; Immunoglobulin G; Indirect Fluorescence Antibody; Leu; LGI1; LGI1 Ab; Neuro; Neurology; Ordinal; Point in time; PR; Prot; QL; Qual; Qualitative; Random; Screen; Serology; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid |
2.69 |
2.68 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 94289-6 |
West Nile virus Ab.Neut |
PrThr |
XXX |
Pt |
Ord |
Neut |
|
ACTIVE |
West Nile virus neutralizing antibody [Presence] in Specimen by Neutralization test |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
94289-6 |
|
Neut |
|
|
Both |
|
|
|
0 |
WNV NAb Spec Ql Nt |
|
|
|
|
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Conventional virus neutralization test; cVNT; ID; Infectious Disease; InfectiousDisease; Microbiology; Misc; Miscellaneous; NAb; NEUTRALIZATION; Neutralization test; NT; Ordinal; Other; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Serum virus neutralization; Spec; SVN; To be specified in another part of the message; Unspecified; Virus neutralization test; VNT; WNV |
2.72 |
2.68 |
|
|
|
|
|
|
|
|
|
|
Release 2.72: COMPONENT: Updated "Ab" to "Ab.Neut" since this test is detecting neutralizing antibodies.; |
0 |
| 9429-2 |
Indium |
MCnc |
XXX |
Pt |
Qn |
|
|
ACTIVE |
Indium [Mass/volume] in Specimen |
|
MIN |
DefinitionDescription |
|
|
ug/dL |
|
|
|
|
|
|
DRUG/TOX |
|
9429-2 |
|
|
|
|
Both |
|
|
|
0 |
Indium Spec-mCnc |
|
|
|
Y |
|
DRUG/TOXICOLOGY; Drugs; In; Level; Mass concentration; Misc; Miscellaneous; Other; Point in time; QNT; Quan; Quant; Quantitative; Random; Spec; To be specified in another part of the message; Unspecified |
2.7 |
1.0i |
|
|
|
|
|
|
|
ug/dL |
|
|
|
0 |
| 94290-4 |
Saint Louis encephalitis virus Ab.Neut |
PrThr |
XXX |
Pt |
Ord |
Neut |
|
ACTIVE |
Saint Louis encephalitis virus neutralizing antibody [Presence] in Specimen by Neutralization test |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
94290-4 |
|
Neut |
|
|
Both |
|
|
|
0 |
SLEV NAb Spec Ql Nt |
|
|
|
|
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Conventional virus neutralization test; cVNT; Enc; Enceph; Encephalomyelitis; ID; Infectious Disease; InfectiousDisease; Microbiology; Misc; Miscellaneous; NAb; NEUTRALIZATION; Neutralization test; NT; Ordinal; Other; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Serum virus neutralization; SLE virus; SLEV; Spec; St Louis; SVN; To be specified in another part of the message; Unspecified; Virus neutralization test; VNT |
2.72 |
2.68 |
|
|
|
|
|
|
|
|
|
|
Release 2.72: COMPONENT: Updated "Ab" to "Ab.Neut" since this test is detecting neutralizing antibodies.; |
0 |
| 94291-2 |
Hydroxybupropion |
PrThr |
Ser/Plas |
Pt |
Ord |
Screen |
|
ACTIVE |
Hydroxybupropion [Presence] in Serum or Plasma by Screen method |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
94291-2 |
|
Screen |
|
|
Both |
|
|
|
0 |
OH-bupropion SerPl Ql Scn |
|
|
|
|
|
6-hydroxybupropion; Bupropion metabolite; BW 306U; DRUG/TOXICOLOGY; Drugs; OH-bupropion; Ordinal; Pl; Plasma; Plsm; Point in time; PR; QL; Qual; Qualitative; Random; Scn; Scr; Screen; Scrn; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.68 |
2.68 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
| 94292-0 |
Citalopram+Escitalopram |
PrThr |
Ser/Plas |
Pt |
Ord |
Screen |
|
ACTIVE |
Citalopram+Escitalopram [Presence] in Serum or Plasma by Screen method |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
94292-0 |
|
Screen |
|
|
Both |
|
|
|
0 |
Citalopram+Escitalopram SerPl Ql Scn |
|
|
|
|
|
Addiction; Celexa; Cipralex; Cipramil; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; Illicit; Lexamil; Lexapro; Ordinal; Pl; Plasma; Plsm; Point in time; PotentialForAbuse; PR; QL; Qual; Qualitative; Random; Scn; Scr; Screen; Scrn; Seroplex; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.68 |
2.68 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
| 94293-8 |
Citalopram+Escitalopram |
MCnc |
Ser/Plas |
Pt |
Qn |
Confirm |
|
ACTIVE |
Citalopram+Escitalopram [Mass/volume] in Serum or Plasma by Confirmatory method |
|
ADD |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
94293-8 |
|
Confirm |
|
|
Both |
|
|
|
0 |
Citalopram+Escitalopram SerPl Cfm-mCnc |
|
|
|
|
|
Addiction; Celexa; Cfm; Cipralex; Cipramil; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; GCMS; Illicit; LC/MS/MS; Level; Lexamil; Lexapro; Mass concentration; Pl; Plasma; Plsm; Point in time; PotentialForAbuse; QNT; Quan; Quant; Quantitative; Random; Seroplex; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.68 |
2.68 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
| 94294-6 |
Norcitalopram |
PrThr |
Ser/Plas |
Pt |
Ord |
Screen |
|
ACTIVE |
Norcitalopram [Presence] in Serum or Plasma by Screen method |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
94294-6 |
|
Screen |
|
|
Both |
|
|
|
0 |
Norcitalopram SerPl Ql Scn |
|
|
|
|
|
Citalopram metabolite; Desmeth; Desmethylcitalopram; DRUG/TOXICOLOGY; Drugs; Ordinal; Pl; Plasma; Plsm; Point in time; PR; QL; Qual; Qualitative; Random; Scn; Scr; Screen; Scrn; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.68 |
2.68 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
| 94295-3 |
Duloxetine |
PrThr |
Ser/Plas |
Pt |
Ord |
Screen |
|
ACTIVE |
DULoxetine [Presence] in Serum or Plasma by Screen method |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
94295-3 |
|
Screen |
|
|
Both |
|
|
|
0 |
DULoxetine SerPl Ql Scn |
|
|
|
|
|
Cymbalta; DRUG/TOXICOLOGY; Drugs; Ordinal; Pl; Plasma; Plsm; Point in time; PR; QL; Qual; Qualitative; Random; Scn; Scr; Screen; Scrn; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Yentreve |
2.68 |
2.68 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
| 94296-1 |
Norfluvoxamine |
PrThr |
Ser/Plas |
Pt |
Ord |
Screen |
|
ACTIVE |
Norfluvoxamine [Presence] in Serum or Plasma by Screen method |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
94296-1 |
|
Screen |
|
|
Both |
|
|
|
0 |
Norfluvoxamine SerPl Ql Scn |
|
|
|
|
|
DRUG/TOXICOLOGY; Drugs; Ordinal; Pl; Plasma; Plsm; Point in time; PR; QL; Qual; Qualitative; Random; Scn; Scr; Screen; Scrn; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.68 |
2.68 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
| 94297-9 |
Norfluvoxamine |
MCnc |
Ser/Plas |
Pt |
Qn |
Confirm |
|
ACTIVE |
Norfluvoxamine [Mass/volume] in Serum or Plasma by Confirmatory method |
|
ADD |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
94297-9 |
|
Confirm |
|
|
Both |
|
|
|
0 |
Norfluvoxamine SerPl Cfm-mCnc |
|
|
|
|
|
Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; GCMS; LC/MS/MS; Level; Mass concentration; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.68 |
2.68 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
| 94298-7 |
O-desmethylvenlafaxine |
PrThr |
Ser/Plas |
Pt |
Ord |
Screen |
|
ACTIVE |
O-desmethylvenlafaxine [Presence] in Serum or Plasma by Screen method |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
94298-7 |
|
Screen |
|
|
Both |
|
|
|
0 |
ODV SerPl Ql Scn |
|
|
|
|
|
Desmeth; Desvenlafaxine; DRUG/TOXICOLOGY; Drugs; Norvenlafaxin; Norvenlafaxine; O-desmethylvenlafaxine; ODV; Ordinal; Pl; Plasma; Plsm; Point in time; PR; Pristiq; QL; Qual; Qualitative; Random; Scn; Scr; Screen; Scrn; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Venlafaxine metabolite |
2.69 |
2.68 |
|
|
|
|
|
|
|
ng/mL |
|
|
Release 2.69: COMPONENT: Resolve ambiguity in name norvenlafaxine, which has O-desmethyl and N-desmethyl forms, O-desmethyl reported to be the one measured in assays.; |
0 |
| 94299-5 |
Vilazodone |
PrThr |
Ser/Plas |
Pt |
Ord |
Screen |
|
ACTIVE |
Vilazodone [Presence] in Serum or Plasma by Screen method |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
94299-5 |
|
Screen |
|
|
Both |
|
|
|
0 |
Vilaz SerPl Ql Scn |
|
|
|
|
|
Addiction; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; Illicit; Ordinal; Pl; Plasma; Plsm; Point in time; PotentialForAbuse; PR; QL; Qual; Qualitative; Random; Scn; Scr; Screen; Scrn; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Viibryd |
2.68 |
2.68 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
| 943-1 |
C Ab |
PrThr |
Ser/Plas^BPU |
Pt |
Ord |
|
|
ACTIVE |
C Ab [Presence] in Serum or Plasma from Blood product unit |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
BLDBK |
|
943-1 |
|
|
|
|
Observation |
|
|
|
0 |
C Ab SerPl BPU Ql |
|
|
|
|
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; BLOOD BANK; Blood product unit; Blood Product Unit (Pack); Ordinal; Pl; Plasma; Plsm; Point in time; PR; QL; Qual; Qualitative; Random; Rh Blood Group System; Screen; SerP; SerPl; SerPl^bpu; SerPlas; Serum; Serum or plasma; SR |
2.73 |
1 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 9430-0 |
Isobutylcarbinol |
MCnc |
Bld |
Pt |
Qn |
|
|
ACTIVE |
Isobutylcarbinol [Mass/volume] in Blood |
|
MIN |
DefinitionDescription |
|
|
ug/mL |
|
|
|
|
|
|
DRUG/TOX |
|
9430-0 |
|
|
|
|
Both |
|
|
|
0 |
Isobutylcarbinol Bld-mCnc |
|
|
|
Y |
|
Blood; DRUG/TOXICOLOGY; Drugs; Isoamyl alcohol; Isopentanol; Isopentyl alcohol; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; WB; Whole blood |
2.73 |
1.0i |
|
|
|
|
|
|
|
ug/mL |
|
|
|
0 |
| 94300-1 |
Vilazodone |
MCnc |
Ser/Plas |
Pt |
Qn |
Confirm |
|
ACTIVE |
Vilazodone [Mass/volume] in Serum or Plasma by Confirmatory method |
|
ADD |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
94300-1 |
|
Confirm |
|
|
Both |
|
|
|
0 |
Vilaz SerPl Cfm-mCnc |
|
|
|
|
|
Addiction; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; GCMS; Illicit; LC/MS/MS; Level; Mass concentration; Pl; Plasma; Plsm; Point in time; PotentialForAbuse; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Viibryd |
2.68 |
2.68 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
| 94301-9 |
Vortioxetine |
PrThr |
Ser/Plas |
Pt |
Ord |
Screen |
|
ACTIVE |
Vortioxetine [Presence] in Serum or Plasma by Screen method |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
94301-9 |
|
Screen |
|
|
Both |
|
|
|
0 |
Vortioxetine SerPl Ql Scn |
|
|
|
|
|
DRUG/TOXICOLOGY; Drugs; Ordinal; Pl; Plasma; Plsm; Point in time; PR; QL; Qual; Qualitative; Random; Scn; Scr; Screen; Scrn; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.68 |
2.68 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
| 94302-7 |
Vortioxetine |
MCnc |
Ser/Plas |
Pt |
Qn |
Confirm |
|
ACTIVE |
Vortioxetine [Mass/volume] in Serum or Plasma by Confirmatory method |
|
ADD |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
94302-7 |
|
Confirm |
|
|
Both |
|
|
|
0 |
Vortioxetine SerPl Cfm-mCnc |
|
|
|
|
|
Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; GCMS; LC/MS/MS; Level; Mass concentration; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.68 |
2.68 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
| 94303-5 |
Pregnenolone & 17-Hydroxypregnenolone panel |
- |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Pregnenolone and 17-Hydroxypregnenolone panel - Serum or Plasma |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.CHEM |
|
94303-5 |
|
|
|
|
Order |
|
|
|
0 |
Preg + 17-OH Preg pnl SerPl |
|
|
|
|
|
17 alpha-Hydroxypregnanolone; 17 hydroxy pregnenolone; 17-alpha-Hydroxypregnenolone; 17alpha-Hydroxypregnenolone; 17-OH Pregnenolone; 17OH-Preg; Chemistry; Pan; PANEL.CHEMISTRY; Panl; Pl; Plasma; Plsm; Pnl; Point in time; Preg + 17-OH Preg pnl; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.68 |
2.68 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
